Loss of exclusivity tracking, explained.

What loss of exclusivity means: the day a cheaper copy can legally launch

The five stages of an entry date, from first patent to generic launch

1. The patent estate is builtMolecule first, around 20 years of term from filing. Later patents cover formulations, uses and processes.
2. Approval starts the regulatory clocksExclusivities begin, patents are listed, and a term extension must be requested within 60 days.
3. The date is tracked and challengedChallengers file. Courts, the patent office and settlements move the date. This step is the subject of this guide.
4. The date is decided and planned onCounsel sets a date of record and a downside case, an earlier date that could happen. Finance builds the plan on them.
5. The first copy launchesVolume moves quickly for chemically made drugs, known as small molecules, and more slowly and unevenly for biologics.

Step 3 runs for years, and most of the events that matter happen during it.

Patent expiry is rarely the launch date, and other LOE traps

The words on an LOE calendar: Paragraph IV, date of record, SPC and acceleration clause

Fourteen terms are defined in the summary page.

The generic entry date formula: licensed date or the last barrier an unlicensed challenger faces

In shortFor one product in one market, expected entry is the earlier of two dates: the licensed date a settled challenger holds, and the end of the last barrier an unsettled challenger still faces. Every barrier needs its own end date, its own source and its own view on whether it will hold.

That formula hides most of the work. "Barrier" covers a compound patent, a formulation patent, a method-of-use patent that a generic may avoid by leaving that use off its label, a process patent a challenger may not use, a regulatory exclusivity that bars approval whatever the patents say, and a court-ordered or statutory stay. A barrier counts only if it applies to that challenger's product, so the same patent can block one filer and leave another free.

Hatch-Waxman deadlines: NCE-1, the Paragraph IV notice, the 45-day suit window and the 30-month stay

In shortThe US law for chemical drugs, known as Hatch-Waxman, runs on fixed periods. Five years of new chemical entity exclusivity, with Paragraph IV filings allowed after four. A notice within 20 days of FDA's filing letter. 45 days to sue. A 30-month stay, a hold on FDA's approval, if you do. 180 days of exclusivity for the first filer. Miss a suit window and the stay is gone.

The 7.5-year point is our arithmetic from the statute; it applies when suit is filed in the fifth year after approval.6 The 45 days and 30 months count from receipt.6

Biosimilar entry dates: 12 years of exclusivity, the patent list exchange and a slower decline

In shortA biologic gets 12 years before FDA can approve a biosimilar, and a biosimilar application cannot be filed until year four. The patents are handled through a staged exchange of lists between the applicant and the biologic's maker, the reference sponsor, nicknamed the patent dance. There is no 30-month stay. Instead, a biosimilar maker gives 180 days' notice of launch. Share usually moves more slowly than for small molecules.

Since June 2021, FDA has published in the Purple Book, its list of licensed biologics, the patent lists sponsors give to biosimilar applicants, within 30 days of a list going to an applicant, with monthly updates planned.17 That is later than the Orange Book's view: a biologic's patents can stay unlisted until a biosimilar applicant appears. The Purple Book's reference product exclusivity date adds any six-month pediatric period to the 12 years.17

One product is no rule. As of June 2026, Samsung Bioepis counted 96 biosimilars approved across 21 molecules, 71 of them launched, with an average 47% share and a 52% fall in average sales price within five years of the first launch.23 Plan on your own product's channel, payer mix and competitors.

SPC expiry, EU data protection and why Germany's date differs from the US date

In shortEurope has no Orange Book, no 45-day clock and no 30-month stay. A supplementary protection certificate extends the basic patent by up to five years, capped at 15 years of protection from first authorization. Data and market protection runs 8 + 2 + 1 years: eight of data protection, two more of market protection and one more for a significant new indication. Proposed changes are not law. National courts and the Unified Patent Court decide validity, so a single European date can split by country.

China and Japan: patent term extensions on their own rules

China's amended Patent Law, in force from June 1, 2021, added patent term extension of up to five years where less than 14 years remain after approval.33 Its patent linkage system holds a generic's approval for nine months once a case is filed, with no such period for biologics, under measures effective July 4, 2021.33,34 We read law firm notes on these and did not read China's own texts or its later implementing rules.

Japan's Patent Act allows an extension of up to five years where a required approval kept the invention from being worked.35 We read an unofficial translation, amended to 2018, and did not read the Japan Patent Office's own text. The fictional screens show a Japanese re-examination period of 8 years, and 10 for an orphan drug: sample values we did not check. In each country, an entry date needs a local reading by someone who practices there.

The opposition periods above come from WIPO's summary of the EPO system and a law firm's report. We did not read the European Patent Convention or its Rule 79 on the EPO's own site.

Calculating patent term extension and an SPC, worked through to the day

In shortTerm extension and SPC calculations are arithmetic on legal dates, with caps that bite. A US compound patent with a long clinical program often hits the 14-year cap before the 5-year cap. Six pediatric months then sit on top. The worked example lands on September 15, 2033 in the United States and March 12, 2034 in Germany, for the same molecule.

The dates are the fictional example's. The rules are real. The UK SPC in the same example already has its pediatric extension.

Two traps need their own line. First, only one US patent can be extended for a product, so the choice of which patent to extend is a decision with a price.7

Second, term adjustment can interact with double patenting. Term adjustment is time the patent office adds to a term, mainly for its own delays.36 Double patenting is the doctrine that stops an owner stretching protection with a second patent on an essentially identical invention.37

In Allergan v. MSN (August 13, 2024), the Federal Circuit held that a first-filed, first-issued, later-expiring claim cannot be invalidated for double patenting by a later-filed, later-issued, earlier-expiring reference claim with a common priority date.37 In plain terms, the first patent in a family can keep its adjusted term. We read a law firm's summary and did not read the opinion. A date resting on term adjustment for a later family member needs a lawyer's read.

Settlement acceleration clauses: how a licensed entry date moves and what triggers it

In shortCompanies filed about 200 final patent settlements a year with the FTC in the latest years reported, and nearly every one that licenses a launch date also says what would bring it forward. FTC reports name the common triggers: another generic selling, another company's court win, a license to a third party with an earlier date, falling brand sales, or a new product. The exact words decide what the date does.

Triggers from the FTC's FY 2021 overview.5 The questions are ours. Settlements can also limit quantities: 11 FY 2021 agreements restricted how much the generic could sell for a time.5 Bristol Myers Squibb's 2025 filing shows that pattern: volume-limited generic licenses for Revlimid, no longer limited from January 31, 2026.4

Why every clause in six settlements has to be read again after one order

The fictional section 3.3 reads: if a third party starts selling a generic after a final court decision holding each asserted claim of both the '418 and '772 patents invalid, unenforceable or not infringed, the licensed entry date moves to that party's first sale.

Follow it through. Cancellation of the '418 alone leaves the '772 blocking until May 2, 2036, later than the licensed March 1, 2036. Both must fall. Then a third party must launch, and it still has to wait for the '207 to end on September 15, 2033. That is why the downside date is that date.

Two points a careful reader catches. The clause says "court". A patent office decision to cancel claims is the Office's own, and it becomes final only after any appeal, so whether and when it satisfies the clause is a contract question for counsel. And five more agreements are "on substantially identical terms", a phrase that invites someone to check the differences. Never paraphrase a trigger when you can quote it.

How three makers state their own entry dates: Eliquis, Opdivo and Rinvoq

Filings for 2025, read November 3, 2026. These are the companies' statements about their own products and may have changed.

Inter partes review after October 2025: the Director decides, institution falls to 41%, and a rule waits

In shortInter partes review (IPR) lets a challenger ask the US patent office to cancel claims, on a one-year timetable from institution, the decision to start a review. Since October 20, 2025 the USPTO Director makes that decision. Counting post-grant review too, institution by petition fell from 68% in fiscal 2024 to 50% in fiscal 2025 and 41% in fiscal 2026, with bio and pharma at 55% on 71 decisions. A rule proposed to bar many parallel challenges has been under White House review as a final rule since July 22, 2026, with no public final text.

Post-grant review, counted in the first chart, is a similar challenge open for nine months after grant.40 The process changed twice in these years. A USPTO memorandum of March 26, 2025 had the Director decide first whether to deny a petition on discretionary grounds, while panels of judges decided the merits.41 Fiscal 2025 stood at 69% through February 2025 and ended at 50%.42,38 Since October 20, 2025 the Director decides the whole question, after consulting at least three judges. Routine decisions come as a summary notice, and petitions already referred to a panel stayed there.41

Once a review starts, a three-judge panel runs the trial, with a final decision due one year from institution, extendable by up to six months for good cause.41,28 A challenger must file within a year of being served with a complaint on that patent.43

Orange Book patents are a small share of these petitions. USPTO's study shows that from 2012 to July 2025, Orange Book patents saw a 62% institution rate (307 of 499), and that under 1.4% of petitions challenged Orange Book patents in fiscal 2025 through July, down from a peak of 7.5% in fiscal 2016.39

You may also see a fall from about 65% to about 37%. That is a trade report of a USPTO webinar chart, setting October 2024 against February 2026 without stating the base.44

The 37% matches USPTO's own year-to-date figure for fiscal 2026 through February: 236 instituted, 404 denied.45 The full year then closed at 41%, and by our subtraction from USPTO's July and September tables, August and September ran at 36 instituted of 57 decided.46,38 We read no USPTO table giving the 65%. So 37% and 41% are the same count at two dates, and the full-year figure is the one to plan on.

Scenario analysis for LOE: which events move the date and what a downside is worth

In shortOnly some events move an entry date. Many change only the odds or a clock. A good tracker separates these, carries one date of record plus a downside with a stated likelihood, and records why. The likelihood is a judgment by counsel. No public benchmark exists for how accurate such judgments are, so record them and score yourself.

What the Dravenzo downside is worth: $7.6 billion at 20% or at 40%

Fictional example; our arithmetic for the weighted figures. Flat revenue is a simplification: use your plan's erosion curve. A likelihood is an input someone must own, and the 40% is that example's proposal.

Common LOE calendar errors: a clock counted from the letter date, a clause nobody quoted and ten more

In shortMost of these are errors of attention, and few involve hard law. A clock counted from the wrong day, a date copied from an old plan, an extension counted before it is granted. No public study counts how often they happen, so test your own calendar against this list.

The patent cliff to 2030 and what generic competition does to price and share

In shortThe analyst firm Evaluate says over $300 billion in prescription drug revenue loses exclusivity between 2025 and 2030. FDA found generic prices 39% below brand with one competitor and over 95% below with six or more. Brands held 18% of unit share a year after generic entry, for larger products. Exclusivity lasted about 13 years for those products. A date that is wrong by months moves large sums.

Evaluate's newer forecast says three named large companies alone have up to $500 billion in combined sales at risk through 2032.55 Treat these as analyst estimates that depend on method and window. No public figure says how often a date of record turns out wrong, or what that costs. What a reader can measure is below, in Part C.

Where a wrong entry date lands inside a company

AI on patent expiry and settlements: ethics and privilege apply, and FDA and EU AI texts mostly stop short

In shortSoftware can watch sources, read documents, do date arithmetic and count clocks. Lawyers keep the judgment: whether a patent will hold, what a clause means, whether to sue. No regulator has written a rule specifically for this work. The live constraints are legal ethics, privilege and the confidentiality of settlements. FDA's and the EU's AI texts mostly do not reach it.

Six LOE tasks split between software and a named person

No public figure measures how accurately AI reads settlement clauses or computes patent term. Before relying on a tool, test it on planted clause changes and on products whose dates you already know.

Who keeps an LOE calendar today: spreadsheets, docket alerts and a slide to Finance

In shortA common setup has IP strategy keeping a patent-term spreadsheet per product, refreshed for the annual plan. Outside counsel send docket alerts by email. A data subscription shows competitors' filings. Settlement terms sit in a contract system. The decided date reaches Finance as a slide, and our own estimate is about three weeks from event to decided date. No published study measures this.

Five roles an entry date passes through, from chief patent counsel to Finance

Quotes are from the guide's fictional roles.

Five ways to keep an entry date, and what each one misses

Northwind Bio's '418 review: date holds at March 1, 2036, the downside goes to 40%, Finance knows that morning

In shortThis is the example from the top of the page, inside the product. On Friday, October 2, 2026 at 5:42 pm, an order enters on the docket instituting review of all 14 claims of Dravenzo's '418 formulation patent. Six specialist agents read it, re-read six settlements and recompute. Omar Haddad, the chief patent counsel, opens the screen on Wednesday and decides in minutes.

1

The exclusivity horizon opens on the latest event

Each product and market is a lane from today to its expected generic or biosimilar entry, with the downside range hatched. Dravenzo US runs to March 2036, Veltrimab US to January 2033, Talvoren US to August 2027, Orvanthe to November 2038. Beside the lanes, six statutory clocks count down.

The nearest clock is the 45-day window on Brightwell Pharma's notice, with 43 days left. The latest source event sits on top with its source, and with what it could do.

2

One click shows what the order could do

"Show the effect on the horizon" focuses the Dravenzo US lane. The date of record holds at March 1, 2036, and the downside appears in red: generic entry September 15, 2033, 2 years and 6 months earlier, if the '418 falls at the patent board and the '772 is lost at trial in January, because then the six settled filers accelerate.

The proposed likelihood moves from 20% to 40%, with $7.6 billion of US revenue at risk. The patent owner response clock lights up on the right.

3

Six agents worked the change before anyone asked

The Source Watcher picked the order up from the docket feed at 5:42 pm. The Patent & Exclusivity Reader confirmed claims 1 to 14 on all grounds, a response by January 4, 2027 and a final decision by October 2, 2027. The Settlement Terms Reader re-read six agreements. The Entry Date Calculator found the downside now needs the '772 trial to go against Northwind as well. The Clock Keeper added two clocks, and the run then waits for Omar.

4

Section 3.3, quoted word for word

The date rests on a clause, so the clause opens at its page. Section 3.3 of the Arden Generics settlement moves the licensed date only if a third party starts selling after a final court decision against each asserted claim of both the '418 and the '772. Access reads "Legal only", and five more agreements follow on substantially identical terms.

Read closely, the clause says "court". A patent board cancellation becomes final only after any appeal, so counsel still has to read how the two fit.

5

Omar decides, and Finance hears that morning

The recommendation is to keep March 1, 2036 and raise the downside from 20% to 40%, "because one of the two required outcomes is now in a forum where challengers often win". Part A gave the record behind those words: among Orange Book petitions reaching a final written decision, half lost every claim, though most petitions never got there.39

Omar could keep 20%, or ask Dana Okafor for the litigation view. He accepts at 9:14 am. Sam Patel in Finance is told and the plan's feed updates. Undo stays available, and the undo would be logged too.

The solution's design targets are 3.6 hours from a source event to a recomputed date, 91% of changes decided by counsel the same day, and 14 of 14 statutory deadlines met, each with an owner from day one. They are targets, to be measured on your own portfolio. About three weeks by spreadsheet is the product team's estimate.

Barrier stacks, what-if switches, the suit window and the board summary on the screens

In shortThe example follows one order. These screens show the rest: dates across 32 product and market pairs, the stack behind a date, outcomes switched on and off, biosimilars, an SPC, the other changes and clocks, source documents, the board summary, the dashboard and the rules your team sets.

Watch, read, compute, count: six agents propose, and counsel decides each date

In shortSix specialist agents do one job each. None of them moves a date of record, files, sues or replies. The chief patent counsel decides dates and likelihoods, litigation counsel decides suits and owns the clocks, and Finance receives decided dates only.

The one job each LOE agent holds, and the line it never crosses

The date of record and suits each have one decider, and Finance receives the result

Every action by a person or an agent is on the audit trail, with who, what and when, and settlement terms stay within Legal roles. Security: SOC 2 Type II audited, with information security managed to ISO 27001. Patent tracking falls outside GxP, the quality rules for drug development and manufacturing, so no GxP claim applies here.

Omar, Priya, Dana, Sam and Dr. Chen on these screens

What the solution reads and leaves you: a cited entry date per market, from patents, dockets and settlements

In shortThe solution reads public sources and your own systems, and writes one thing back: decided dates to the plan's feed. It leaves you a cited date per market, change alerts, scenarios and a board summary, at the scale of a global portfolio.

Where entry date data lives today: IP, contract, docket and planning systems

For each, check whether it has an API, a file feed or an export, and who owns it. Read access is enough, except for the one feed to the plan, which your Finance team approves.

One lost stay or a plan built on old news: the two ways a stale entry date costs you

In shortTwo costs dominate. The first should be rare and is large: a missed window, such as a lost 30-month stay. The second is common and quiet: a plan and a board that run on a date, or an odds estimate, that has already changed. Statutes and filings give you the periods and the scale. The rest you can measure in a week.

Auditing your own LOE calendar: your last ten events, last five notices and one product's clauses

What a late patent date costs that no formula counts

What a cited date per market returns: hours you can count and an avoided error you cannot prove

In shortPut in your own numbers. On hours alone, the case depends on the size of your patent estate, meaning your products and their patents. The largest possible value sits in an avoided error, and you should keep it apart from the hours, because you cannot prove it in advance. Your business case is stronger if it says so plainly.

Six places LOE tracking pays, from finding an event to the board summary

Work out your LOE hours: events, refreshes and what the tool costs

A company with three products and one patent counsel may well decide a good spreadsheet and outside counsel are enough. A global portfolio, several live challengers or a board asking for dates each quarter changes that.

LOE readiness check: score your dates, sources, settlements, clocks and deciders

In shortPick the answer closest to your team today. Eight questions score 0 to 2; the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

What a score of 0 to 6, 7 to 11 or 12 to 16 means for an IP team

Buying LOE software or patent data: 15 questions on citations, clauses, clocks and who decides

In shortAsk every vendor the same questions, us included. The answers show whose date it is, what a value rests on, how settlements stay confidential, and how you could prove it works before you sign.

We found no published independent test of any LOE tracking tool, as of November 2026. A replay of your own last twelve months is the fairest comparison.

An LOE pilot: replay a year of known events on one product and compare its dates with counsel's

In shortPick one product in three markets where you already know what happened last year. Feed the sources in date order, with some changes you plant. See what the tool catches, how quickly, and whether a date it proposes matches what counsel decided. Decide with three numbers.

1. Pick the product: one with live challengers, a settlement and at least two markets outside the US.
2. Write today's answer by hand: stack, clauses, clocks, date and downside, timed.
3. Gather sources and plant changes: a changed clause on a copy, a wrong receipt date, a lapsed patent.
4. Replay the year with counsel deciding as they did, and Legal holding the settlement access.
5. Decide with three numbers: events caught, dates matched, and hours from event to a decided date.

Scoring the replay: events caught, dates matched, hours to a decision, clause accuracy, false alarms

The first three numbers decide. The last two tell you how far to trust them.

Questions people ask about LOE dates, Paragraph IV notices, SPCs and biosimilars

In shortEach answer stands alone. For your own case, ask your patent counsel.